Electrical Supporting Information Materials

Synthesis and antitumor mechanisms of two novel platinum(II) complexes with 3-(2′-benzimidazolyl)-7-methoxycoumarin

Qi-Pin Qin a,c,1, Shu-Long Wang a,l, Ming-Xiong Tan a,* Zhen-Feng Wang a, Xiao-Ling Huang a, Qing-Min Wei a,* Bei-Bei Shi a, Bi-Qun Zou b,c,* and Hong Liang c,*

Table S1. Crystal data and structure refinement details for H-MeOBC.

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Empirical formula</td>
<td>C_{17}N_{2}O_{3}</td>
</tr>
<tr>
<td>Formula weight</td>
<td>280.19</td>
</tr>
<tr>
<td>Temperature/K</td>
<td>296.15</td>
</tr>
<tr>
<td>Crystal system</td>
<td>monoclinic</td>
</tr>
<tr>
<td>Space group</td>
<td>P_{2}1/c</td>
</tr>
<tr>
<td>a/Å</td>
<td>13.2523(7)</td>
</tr>
<tr>
<td>b/Å</td>
<td>8.0408(4)</td>
</tr>
<tr>
<td>c/Å</td>
<td>12.7339(6)</td>
</tr>
<tr>
<td>α/°</td>
<td>90.00</td>
</tr>
<tr>
<td>β/°</td>
<td>91.040(4)</td>
</tr>
<tr>
<td>γ/°</td>
<td>90.00</td>
</tr>
<tr>
<td>Volume/Å^{3}</td>
<td>1356.70(11)</td>
</tr>
<tr>
<td>Z</td>
<td>4</td>
</tr>
<tr>
<td>\rho_{calc} \text{g/cm}^{3}</td>
<td>1.372</td>
</tr>
<tr>
<td>\mu \text{mm}^{-1}</td>
<td>0.098</td>
</tr>
<tr>
<td>F(000)</td>
<td>560.0</td>
</tr>
<tr>
<td>Crystal size/mm^{3}</td>
<td>0.2 \times 0.15 \times 0.1</td>
</tr>
<tr>
<td>Radiation</td>
<td>MoKα (λ = 0.71073)</td>
</tr>
<tr>
<td>2θ range for data collection/°</td>
<td>6.7 to 50</td>
</tr>
<tr>
<td>Index ranges</td>
<td>-12 \leq h \leq 15, -9 \leq k \leq 9, -15 \leq l \leq 15</td>
</tr>
<tr>
<td>Reflections collected</td>
<td>8840</td>
</tr>
<tr>
<td>Independent reflections</td>
<td>2390 [R_{int} = 0.0192, R_{sigma} = 0.0194]</td>
</tr>
<tr>
<td>Data/restraints/parameters</td>
<td>2390/0/199</td>
</tr>
<tr>
<td>Goodness-of-fit on F^2</td>
<td>1.033</td>
</tr>
<tr>
<td>Final R indexes [I\geq2σ (I)]</td>
<td>R_1 = 0.0779, wR_2 = 0.2578</td>
</tr>
<tr>
<td>Final R indexes [all data]</td>
<td>R_1 = 0.0884, wR_2 = 0.2677</td>
</tr>
<tr>
<td>Largest diff. peak/hole / e Å^{-3}</td>
<td>0.75/-0.21</td>
</tr>
</tbody>
</table>

{a R_1 = \Sigma |F_o| - |F_c|/|\Sigma F_o|; b wR_2 = [\Sigma w(F_o^2 - F_c^2)^2/\Sigma w(F_o^2)^2]^{1/2}.}
Table S2. Selected bond lengths (Å) for H-MeOBC.

<table>
<thead>
<tr>
<th>Atom</th>
<th>Atom</th>
<th>Length/Å</th>
<th>Atom</th>
<th>Atom</th>
<th>Length/Å</th>
</tr>
</thead>
<tbody>
<tr>
<td>O1</td>
<td>C6</td>
<td>1.377(4)</td>
<td>O8</td>
<td>C12</td>
<td>1.215(4)</td>
</tr>
<tr>
<td>O1</td>
<td>C12</td>
<td>1.369(4)</td>
<td>C10</td>
<td>C15</td>
<td>1.415(5)</td>
</tr>
<tr>
<td>C2</td>
<td>C3</td>
<td>1.358(4)</td>
<td>C10</td>
<td>C13</td>
<td>1.371(4)</td>
</tr>
<tr>
<td>C2</td>
<td>C9</td>
<td>1.422(5)</td>
<td>N11</td>
<td>C13</td>
<td>1.379(4)</td>
</tr>
<tr>
<td>C3</td>
<td>C12</td>
<td>1.464(4)</td>
<td>C13</td>
<td>N14</td>
<td>1.316(4)</td>
</tr>
<tr>
<td>C3</td>
<td>C13</td>
<td>1.456(4)</td>
<td>N14</td>
<td>C17</td>
<td>1.389(4)</td>
</tr>
<tr>
<td>C4</td>
<td>C6</td>
<td>1.380(4)</td>
<td>N14</td>
<td>C17</td>
<td>1.395(5)</td>
</tr>
<tr>
<td>C4</td>
<td>C10</td>
<td>1.382(5)</td>
<td>C16</td>
<td>C20</td>
<td>1.394(5)</td>
</tr>
<tr>
<td>O5</td>
<td>C10</td>
<td>1.359(4)</td>
<td>C17</td>
<td>C21</td>
<td>1.399(5)</td>
</tr>
<tr>
<td>O5</td>
<td>C18</td>
<td>1.438(4)</td>
<td>C19</td>
<td>C20</td>
<td>1.387(5)</td>
</tr>
<tr>
<td>C6</td>
<td>C9</td>
<td>1.402(4)</td>
<td>C19</td>
<td>C22</td>
<td>1.397(6)</td>
</tr>
<tr>
<td>C7</td>
<td>C9</td>
<td>1.417(5)</td>
<td>C21</td>
<td>C22</td>
<td>1.387(5)</td>
</tr>
<tr>
<td>C7</td>
<td>C15</td>
<td>1.360(5)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table S3. Selected bond angles (°) for H-MeOBC.

<table>
<thead>
<tr>
<th>Atom</th>
<th>Atom</th>
<th>Atom</th>
<th>Angle/°</th>
<th>Atom</th>
<th>Atom</th>
<th>Atom</th>
<th>Angle/°</th>
</tr>
</thead>
<tbody>
<tr>
<td>C12</td>
<td>O1</td>
<td>C6</td>
<td>123.2(2)</td>
<td>O1</td>
<td>C12</td>
<td>C3</td>
<td>117.6(3)</td>
</tr>
<tr>
<td>C3</td>
<td>C2</td>
<td>C9</td>
<td>121.6(3)</td>
<td>O8</td>
<td>C12</td>
<td>O1</td>
<td>116.1(3)</td>
</tr>
<tr>
<td>C2</td>
<td>C3</td>
<td>C12</td>
<td>119.4(3)</td>
<td>O8</td>
<td>C12</td>
<td>C3</td>
<td>126.3(3)</td>
</tr>
<tr>
<td>C2</td>
<td>C3</td>
<td>C13</td>
<td>121.2(3)</td>
<td>N11</td>
<td>C13</td>
<td>C3</td>
<td>123.6(3)</td>
</tr>
<tr>
<td>C13</td>
<td>C3</td>
<td>C12</td>
<td>119.5(3)</td>
<td>N14</td>
<td>C13</td>
<td>C3</td>
<td>123.9(3)</td>
</tr>
<tr>
<td>C6</td>
<td>C4</td>
<td>C10</td>
<td>117.6(3)</td>
<td>N14</td>
<td>C13</td>
<td>N11</td>
<td>112.5(3)</td>
</tr>
<tr>
<td>C10</td>
<td>O5</td>
<td>C18</td>
<td>117.5(3)</td>
<td>C13</td>
<td>N14</td>
<td>C17</td>
<td>104.9(3)</td>
</tr>
<tr>
<td>O1</td>
<td>C6</td>
<td>C4</td>
<td>116.8(3)</td>
<td>C7</td>
<td>C15</td>
<td>C10</td>
<td>119.9(3)</td>
</tr>
<tr>
<td>O1</td>
<td>C6</td>
<td>C9</td>
<td>119.6(3)</td>
<td>N11</td>
<td>C16</td>
<td>C17</td>
<td>104.9(3)</td>
</tr>
<tr>
<td>C4</td>
<td>C6</td>
<td>C9</td>
<td>123.6(3)</td>
<td>N11</td>
<td>C16</td>
<td>C20</td>
<td>132.4(3)</td>
</tr>
<tr>
<td>C15</td>
<td>C7</td>
<td>C9</td>
<td>121.0(3)</td>
<td>C20</td>
<td>C16</td>
<td>C17</td>
<td>122.6(3)</td>
</tr>
<tr>
<td>C6</td>
<td>C9</td>
<td>C2</td>
<td>118.6(3)</td>
<td>N14</td>
<td>C17</td>
<td>C16</td>
<td>110.4(3)</td>
</tr>
<tr>
<td>C6</td>
<td>C9</td>
<td>C7</td>
<td>116.8(3)</td>
<td>N14</td>
<td>C17</td>
<td>C21</td>
<td>129.6(3)</td>
</tr>
<tr>
<td>C7</td>
<td>C9</td>
<td>C2</td>
<td>124.5(3)</td>
<td>C16</td>
<td>C17</td>
<td>C21</td>
<td>120.0(3)</td>
</tr>
<tr>
<td>C4</td>
<td>C10</td>
<td>C15</td>
<td>121.1(3)</td>
<td>C20</td>
<td>C19</td>
<td>C22</td>
<td>121.2(3)</td>
</tr>
<tr>
<td>O5</td>
<td>C10</td>
<td>C4</td>
<td>124.6(3)</td>
<td>C19</td>
<td>C20</td>
<td>C16</td>
<td>116.8(3)</td>
</tr>
<tr>
<td>O5</td>
<td>C10</td>
<td>C15</td>
<td>114.3(3)</td>
<td>C22</td>
<td>C21</td>
<td>C17</td>
<td>117.7(3)</td>
</tr>
<tr>
<td>C13</td>
<td>N11</td>
<td>C16</td>
<td>107.2(3)</td>
<td>C21</td>
<td>C22</td>
<td>C19</td>
<td>121.7(3)</td>
</tr>
</tbody>
</table>
Table S4. Crystal data and structure refinement details for Pt2.

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Empirical formula</td>
<td>( \text{C}<em>{21}\text{H}</em>{23}\text{Cl}_3\text{N}_2\text{O}_5\text{Pt}_2\text{S}_2 )</td>
</tr>
<tr>
<td>Formula weight</td>
<td>944.07</td>
</tr>
<tr>
<td>Temperature/K</td>
<td>296.15</td>
</tr>
<tr>
<td>Crystal system</td>
<td>triclinic</td>
</tr>
<tr>
<td>Space group</td>
<td>P-1</td>
</tr>
<tr>
<td>a/Å</td>
<td>9.4211(4)</td>
</tr>
<tr>
<td>b/Å</td>
<td>12.9359(8)</td>
</tr>
<tr>
<td>c/Å</td>
<td>13.8521(8)</td>
</tr>
<tr>
<td>( \alpha^\circ )</td>
<td>66.332(6)</td>
</tr>
<tr>
<td>( \beta^\circ )</td>
<td>88.609(4)</td>
</tr>
<tr>
<td>( \gamma^\circ )</td>
<td>71.401(5)</td>
</tr>
<tr>
<td>Volume/Å(^3)</td>
<td>1454.91(16)</td>
</tr>
<tr>
<td>Z</td>
<td>2</td>
</tr>
<tr>
<td>( \rho_{\text{calc}} \text{g/cm}^3 )</td>
<td>2.1549</td>
</tr>
<tr>
<td>( \mu \text{mm}^{-1} )</td>
<td>10.054</td>
</tr>
<tr>
<td>F(000)</td>
<td>879.6</td>
</tr>
<tr>
<td>Crystal size/mm(^3)</td>
<td>0.22 × 0.2 × 0.18</td>
</tr>
<tr>
<td>Radiation</td>
<td>Mo K( \alpha ) (( \lambda = 0.71073 ))</td>
</tr>
<tr>
<td>2( \Theta ) range for data collection/(^\circ)</td>
<td>6.54 to 52.74</td>
</tr>
<tr>
<td>Index ranges</td>
<td>-12 ≤ h ≤ 12, -13 ≤ k ≤ 17, -17 ≤ l ≤ 18</td>
</tr>
<tr>
<td>Reflections collected</td>
<td>10849</td>
</tr>
<tr>
<td>Independent reflections</td>
<td>5931 [( R_{\text{int}} = 0.0401, R_{\text{sigma}} = 0.0827 )]</td>
</tr>
<tr>
<td>Data/restraints/parameters</td>
<td>5931/0/320</td>
</tr>
<tr>
<td>Goodness-of-fit on F(^2)</td>
<td>1.044</td>
</tr>
<tr>
<td>Final R indexes [I&gt;=2( \sigma ) (I)]</td>
<td>( R_1 = 0.0528, wR_2 = 0.1259 )</td>
</tr>
<tr>
<td>Final R indexes [all data]</td>
<td>( R_1 = 0.0850, wR_2 = 0.1491 )</td>
</tr>
<tr>
<td>Largest diff. peak/hole / e Å(^3)</td>
<td>4.62/-2.63</td>
</tr>
</tbody>
</table>

\( a \) \( R_1 = \frac{\Sigma ||F_o|| - |F_c||}{\Sigma |F_o||} \); \( b \) \( wR_2 = \left[ \frac{\Sigma w(F_o^2 - F_c^2)^2}{\Sigma w(F_o^2)^2} \right]^{1/2} \).
**Table S5.** Selected bond lengths (Å) for Pt2.

<table>
<thead>
<tr>
<th>Atom 1</th>
<th>Atom 2</th>
<th>Length/Å</th>
<th>Atom 1</th>
<th>Atom 2</th>
<th>Length/Å</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt2</td>
<td>Cl3</td>
<td>2.308(3)</td>
<td>C13</td>
<td>C12</td>
<td>1.375(15)</td>
</tr>
<tr>
<td>Pt2</td>
<td>N2</td>
<td>2.049(10)</td>
<td>C10</td>
<td>C11</td>
<td>1.390(16)</td>
</tr>
<tr>
<td>Pt2</td>
<td>O3</td>
<td>2.012(10)</td>
<td>C10</td>
<td>C9</td>
<td>1.396(16)</td>
</tr>
<tr>
<td>Pt2</td>
<td>S2</td>
<td>2.219(3)</td>
<td>C11</td>
<td>C6</td>
<td>1.378(17)</td>
</tr>
<tr>
<td>Pt1</td>
<td>S1</td>
<td>2.209(4)</td>
<td>C12</td>
<td>C9</td>
<td>1.404(15)</td>
</tr>
<tr>
<td>Pt1</td>
<td>C12</td>
<td>2.311(4)</td>
<td>C16</td>
<td>C21</td>
<td>1.395(17)</td>
</tr>
<tr>
<td>Pt1</td>
<td>N1</td>
<td>2.034(10)</td>
<td>C16</td>
<td>C17</td>
<td>1.383(16)</td>
</tr>
<tr>
<td>Pt1</td>
<td>Cl1</td>
<td>2.295(4)</td>
<td>C9</td>
<td>C8</td>
<td>1.409(16)</td>
</tr>
<tr>
<td>S1</td>
<td>O1</td>
<td>1.431(10)</td>
<td>S2</td>
<td>O2</td>
<td>1.480(10)</td>
</tr>
<tr>
<td>S1</td>
<td>C1</td>
<td>1.756(15)</td>
<td>S2</td>
<td>C3</td>
<td>1.775(13)</td>
</tr>
<tr>
<td>S1</td>
<td>C2</td>
<td>1.749(15)</td>
<td>S2</td>
<td>C4</td>
<td>1.777(16)</td>
</tr>
<tr>
<td>N2</td>
<td>C15</td>
<td>1.371(13)</td>
<td>C20</td>
<td>C19</td>
<td>1.380(19)</td>
</tr>
<tr>
<td>N2</td>
<td>C21</td>
<td>1.397(15)</td>
<td>C20</td>
<td>C21</td>
<td>1.388(17)</td>
</tr>
<tr>
<td>O3</td>
<td>C14</td>
<td>1.294(14)</td>
<td>C19</td>
<td>C18</td>
<td>1.38(2)</td>
</tr>
<tr>
<td>O4</td>
<td>C10</td>
<td>1.393(14)</td>
<td>C17</td>
<td>C18</td>
<td>1.389(19)</td>
</tr>
<tr>
<td>O4</td>
<td>C14</td>
<td>1.332(13)</td>
<td>O5</td>
<td>C6</td>
<td>1.352(15)</td>
</tr>
<tr>
<td>N1</td>
<td>C15</td>
<td>1.361(14)</td>
<td>O5</td>
<td>C5</td>
<td>1.434(16)</td>
</tr>
<tr>
<td>N1</td>
<td>C16</td>
<td>1.394(15)</td>
<td>C6</td>
<td>C7</td>
<td>1.397(17)</td>
</tr>
<tr>
<td>C15</td>
<td>C13</td>
<td>1.440(14)</td>
<td>C8</td>
<td>C7</td>
<td>1.348(17)</td>
</tr>
<tr>
<td>C13</td>
<td>C14</td>
<td>1.427(15)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table S6. Selected bond angles (°) for Pt2.

<table>
<thead>
<tr>
<th>Atom</th>
<th>Atom</th>
<th>Atom</th>
<th>Angle/°</th>
<th>Atom</th>
<th>Atom</th>
<th>Atom</th>
<th>Angle/°</th>
</tr>
</thead>
<tbody>
<tr>
<td>N2</td>
<td>Pt2</td>
<td>Cl3</td>
<td>97.0(3)</td>
<td>C9</td>
<td>C10</td>
<td>O4</td>
<td>119.1(10)</td>
</tr>
<tr>
<td>O3</td>
<td>Pt2</td>
<td>Cl3</td>
<td>172.8(3)</td>
<td>C9</td>
<td>C10</td>
<td>C11</td>
<td>124.4(11)</td>
</tr>
<tr>
<td>O3</td>
<td>Pt2</td>
<td>N2</td>
<td>89.3(4)</td>
<td>O4</td>
<td>C14</td>
<td>O3</td>
<td>113.4(10)</td>
</tr>
<tr>
<td>S2</td>
<td>Pt2</td>
<td>Cl3</td>
<td>87.27(13)</td>
<td>C13</td>
<td>C14</td>
<td>O3</td>
<td>125.0(11)</td>
</tr>
<tr>
<td>S2</td>
<td>Pt2</td>
<td>N2</td>
<td>175.7(3)</td>
<td>C13</td>
<td>C14</td>
<td>O4</td>
<td>121.5(10)</td>
</tr>
<tr>
<td>S2</td>
<td>Pt2</td>
<td>O3</td>
<td>86.5(3)</td>
<td>C6</td>
<td>C11</td>
<td>C10</td>
<td>117.4(12)</td>
</tr>
<tr>
<td>Cl2</td>
<td>Pt1</td>
<td>S1</td>
<td>179.26(15)</td>
<td>C9</td>
<td>C12</td>
<td>C13</td>
<td>122.3(10)</td>
</tr>
<tr>
<td>N1</td>
<td>Pt1</td>
<td>S1</td>
<td>90.6(3)</td>
<td>C21</td>
<td>C16</td>
<td>N1</td>
<td>107.9(10)</td>
</tr>
<tr>
<td>N1</td>
<td>Pt1</td>
<td>Cl2</td>
<td>88.7(3)</td>
<td>C17</td>
<td>C16</td>
<td>N1</td>
<td>128.5(12)</td>
</tr>
<tr>
<td>Cl1</td>
<td>Pt1</td>
<td>S1</td>
<td>91.08(16)</td>
<td>C17</td>
<td>C16</td>
<td>C21</td>
<td>123.5(12)</td>
</tr>
<tr>
<td>Cl1</td>
<td>Pt1</td>
<td>Cl2</td>
<td>89.64(18)</td>
<td>C12</td>
<td>C9</td>
<td>C10</td>
<td>118.6(11)</td>
</tr>
<tr>
<td>Cl1</td>
<td>Pt1</td>
<td>N1</td>
<td>178.0(3)</td>
<td>C8</td>
<td>C9</td>
<td>C10</td>
<td>114.9(11)</td>
</tr>
<tr>
<td>O1</td>
<td>S1</td>
<td>Pt1</td>
<td>116.5(4)</td>
<td>C8</td>
<td>C9</td>
<td>C12</td>
<td>126.5(11)</td>
</tr>
<tr>
<td>C1</td>
<td>S1</td>
<td>Pt1</td>
<td>110.9(6)</td>
<td>O2</td>
<td>S2</td>
<td>Pt2</td>
<td>113.2(4)</td>
</tr>
<tr>
<td>C1</td>
<td>S1</td>
<td>O1</td>
<td>109.2(8)</td>
<td>C3</td>
<td>S2</td>
<td>Pt2</td>
<td>110.9(6)</td>
</tr>
<tr>
<td>C2</td>
<td>S1</td>
<td>Pt1</td>
<td>110.1(6)</td>
<td>C3</td>
<td>S2</td>
<td>O2</td>
<td>108.9(7)</td>
</tr>
<tr>
<td>C2</td>
<td>S1</td>
<td>O1</td>
<td>107.4(7)</td>
<td>C4</td>
<td>S2</td>
<td>Pt2</td>
<td>112.1(5)</td>
</tr>
<tr>
<td>C2</td>
<td>S1</td>
<td>C1</td>
<td>101.7(9)</td>
<td>C4</td>
<td>S2</td>
<td>O2</td>
<td>108.6(7)</td>
</tr>
<tr>
<td>C15</td>
<td>N2</td>
<td>Pt2</td>
<td>122.9(7)</td>
<td>C4</td>
<td>S2</td>
<td>C3</td>
<td>102.5(8)</td>
</tr>
<tr>
<td>C21</td>
<td>N2</td>
<td>Pt2</td>
<td>131.3(8)</td>
<td>C21</td>
<td>C20</td>
<td>C19</td>
<td>118.4(14)</td>
</tr>
<tr>
<td>C21</td>
<td>N2</td>
<td>Cl15</td>
<td>105.7(10)</td>
<td>C18</td>
<td>C19</td>
<td>C20</td>
<td>122.2(13)</td>
</tr>
<tr>
<td>C14</td>
<td>O3</td>
<td>Pt2</td>
<td>126.6(8)</td>
<td>C16</td>
<td>C21</td>
<td>N2</td>
<td>108.2(11)</td>
</tr>
<tr>
<td>C14</td>
<td>O4</td>
<td>Cl10</td>
<td>121.5(9)</td>
<td>C20</td>
<td>C21</td>
<td>N2</td>
<td>133.3(12)</td>
</tr>
<tr>
<td>C15</td>
<td>N1</td>
<td>Pt1</td>
<td>128.6(8)</td>
<td>C20</td>
<td>C21</td>
<td>C16</td>
<td>118.4(12)</td>
</tr>
<tr>
<td>C16</td>
<td>N1</td>
<td>Pt1</td>
<td>121.1(8)</td>
<td>C18</td>
<td>C17</td>
<td>C16</td>
<td>116.6(13)</td>
</tr>
<tr>
<td>C16</td>
<td>N1</td>
<td>Cl15</td>
<td>106.3(10)</td>
<td>C17</td>
<td>C18</td>
<td>C19</td>
<td>120.7(13)</td>
</tr>
<tr>
<td>N1</td>
<td>C15</td>
<td>N2</td>
<td>111.8(10)</td>
<td>C5</td>
<td>O5</td>
<td>C6</td>
<td>116.7(11)</td>
</tr>
<tr>
<td>C13</td>
<td>C15</td>
<td>N2</td>
<td>126.6(10)</td>
<td>O5</td>
<td>C6</td>
<td>C11</td>
<td>124.6(12)</td>
</tr>
<tr>
<td>C13</td>
<td>C15</td>
<td>N1</td>
<td>121.6(10)</td>
<td>C7</td>
<td>C6</td>
<td>C11</td>
<td>120.2(12)</td>
</tr>
<tr>
<td>C14</td>
<td>C13</td>
<td>Cl15</td>
<td>121.5(10)</td>
<td>C7</td>
<td>C6</td>
<td>O5</td>
<td>115.1(11)</td>
</tr>
<tr>
<td>C12</td>
<td>C13</td>
<td>Cl15</td>
<td>121.9(10)</td>
<td>C7</td>
<td>C8</td>
<td>C9</td>
<td>122.4(12)</td>
</tr>
<tr>
<td>C12</td>
<td>C13</td>
<td>Cl14</td>
<td>116.6(10)</td>
<td>C8</td>
<td>C7</td>
<td>C6</td>
<td>120.6(12)</td>
</tr>
<tr>
<td>C11</td>
<td>C10</td>
<td>O4</td>
<td>116.5(11)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table S7. Inhibitory rates (%) of \textit{cis}-Pt(\textit{DMSO})_2\textit{Cl}_2, cisplatin, the ligand H-MeOBC, the Pt(II) complexes \textit{Pt1} and \textit{Pt2} toward on the selected six human cells for 48 h.

<table>
<thead>
<tr>
<th>Compounds</th>
<th>HeLa</th>
<th>Hep-G2</th>
<th>SK-OV-3/DDP</th>
<th>SK-OV-3</th>
<th>MGC80-3</th>
<th>HL-7702</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-O\textit{Me}</td>
<td>25.06±1.06</td>
<td>28.12±1.74</td>
<td>30.15±2.06</td>
<td>24.18±1.91</td>
<td>20.11±0.75</td>
<td>20.32±0.33</td>
</tr>
<tr>
<td>\textit{Pt1}</td>
<td>38.96±0.51</td>
<td>32.71±1.17</td>
<td>65.13±0.45</td>
<td>35.26±0.52</td>
<td>36.02±1.60</td>
<td>24.03±0.88</td>
</tr>
<tr>
<td>\textit{Pt2}</td>
<td>42.35±1.06</td>
<td>40.15±1.02</td>
<td>85.99±0.29</td>
<td>41.82±1.10</td>
<td>40.56±0.79</td>
<td>23.99±1.78</td>
</tr>
<tr>
<td>vehicle (1% DMSO)</td>
<td>10.23±0.56</td>
<td>13.05±2.01</td>
<td>9.15±1.54</td>
<td>13.02±1.97</td>
<td>10.23±1.01</td>
<td>11.04±1.07</td>
</tr>
<tr>
<td>\textit{cis}-Pt(\textit{DMSO})_2\textit{Cl}_2 b</td>
<td>22.03±1.36</td>
<td>18.06±1.12</td>
<td>23.20±1.05</td>
<td>19.23±0.95</td>
<td>23.54±1.78</td>
<td>25.03±1.65</td>
</tr>
<tr>
<td>Cisplatin b</td>
<td>62.03±1.13</td>
<td>65.18±0.85</td>
<td>40.15±1.89</td>
<td>59.15±0.52</td>
<td>58.66±0.85</td>
<td>60.23±0.59</td>
</tr>
</tbody>
</table>

Results represent mean ± SD of at least five independent experiments. SD represents the standard deviation. \(^a\) The concentration is 20 \(\mu\text{M}. \(^b\) The concentration is 100 \(\mu\text{M}. \(^c\) Cisplatin was dissolved at a concentration of 1.0 mM in 0.154 M NaCl.
Fig. S1. $^1$H NMR (400MHz, DMSO-d$_6$) for the ligand H-MeOBC

Fig. S2. $^{13}$C NMR (101MHz, DMSO-d$_6$) for the ligand H-MeOBC
Fig. S3. ESI-MS spectra of the ligand H-MeOBC

Fig. S4. IR (KBr) spectra of Pt1
Fig. S5. $^1$H NMR (600MHz, DMSO-d$_6$) for Pt1
Fig. S6. The mass spectra of Pt1 in Tris-HCl buffer solution (containing 5% DMSO) for 0 h (top) and 48 h (down), respectively.
Fig. S7. IR (KBr) spectra of Pt2

Fig. S8. $^1$H NMR (600MHz, DMSO-$d_6$) for Pt2
Fig. S9. The mass spectra of Pt2 in Tris-HCl buffer solution (containing 5% DMSO) for 0 h (top) and 48 h (down), respectively.
Fig. S10. UV-Vis absorption spectra of \textbf{Pt1} and \textbf{Pt2} ($2.0 \times 10^{-5}$ M) in TBS (Tris-HCl buffer solution, 10 mM, pH 7.35) solution in the time course 0 and 48 h, respectively.
Fig. S11. HPLC spectra for the H-MeOBC ligand and its two Pt(II) complexes (2.0×10⁻³ M) in DMSO with 0 h and 48 h, respectively. Column: InertSustain C18 column (LC-20AT, SPD-20A HPLC COLUMN, 150mm×5.0 μm I.D.). Column temperature: 40 °C. Mobile phase: methol/H₂O containing 0.01% TFA (90:20 methol/H₂O). Flow rate: 1.0 mL/min. Injection volume: 2.0×10⁻⁵ M.
Fig. S11. FID Assay for Pt2 on DNA

Table S8. FID assay for Pt2 on DNA.

<table>
<thead>
<tr>
<th></th>
<th>PT2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pu27 DC50</td>
<td>0.35</td>
</tr>
<tr>
<td>HTG21 DC50</td>
<td>0.59</td>
</tr>
<tr>
<td>c-kit-1 DC50</td>
<td>2.00</td>
</tr>
<tr>
<td>c-kit-2 DC50</td>
<td>1.07</td>
</tr>
<tr>
<td>Pu22 DC50</td>
<td>1.39</td>
</tr>
<tr>
<td>Pu39 DC50</td>
<td>2.09</td>
</tr>
<tr>
<td>ctDNA DC50</td>
<td>&gt;2.5</td>
</tr>
</tbody>
</table>

DC50 obtained with μM.
Table S9. Sequences of oligomers (primers) used in this work, which were obtained from Shanghai Sangon Biological Engineering Technology & Services (Shanghai, China).

<table>
<thead>
<tr>
<th>oligomer</th>
<th>sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pu27</td>
<td>5′-TGGGGAGGGTGAGGGTGAGGGTAAGGG-3′</td>
</tr>
<tr>
<td>Pu39</td>
<td>5′-AGGGCGGGCGGGGGAGGAAGGGGGCGGGAGCGGGGCTG-3′</td>
</tr>
<tr>
<td>c-kit-2</td>
<td>5′-CGGGCGGGGCCATAGGGAGGCT-3′</td>
</tr>
<tr>
<td>HTG21</td>
<td>5′-GGGTTAGGGTTAGGGTTAGGG-3′</td>
</tr>
<tr>
<td>c-kit-1</td>
<td>5′-CGGGCGGGCAGCAGGGTGGG-3′</td>
</tr>
<tr>
<td>Pu22</td>
<td>5′-TGAGGGTGAGGTGGGTTAGGG-3′</td>
</tr>
</tbody>
</table>
| c-myc    | Ts: 5′-TGGGTCCATAGGAAGGAACA-3′  
|          | Cx: 5′-GTGGCACTCCTTTAGGACCT-3′ |
| hTERT    | Ts: 5′-TGGTCTTCAGGAGCTCCGAGCG-3′  
|          | Cx: 5′-CATCCACATAGGGCCACCAGCT-3′ |
| GAPDH    | Ts: 5′-GCCTCTTGCACGACCAACTG-3′  
|          | Cx: 5′-CGGAAGGCGCATGCTGTCAG-3′ |
Table S10. Abbreviations in this work

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBS</td>
<td>Tris-HCl buffer</td>
</tr>
<tr>
<td>MTT</td>
<td>3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</td>
</tr>
<tr>
<td>ROS</td>
<td>reactive oxygen species</td>
</tr>
<tr>
<td>IC&lt;sub&gt;50&lt;/sub&gt;</td>
<td>half maximal inhibitory concentration</td>
</tr>
<tr>
<td>G4 DNA</td>
<td>G-quadruplex DNA</td>
</tr>
<tr>
<td>MGC80-3</td>
<td>human gastric mucous adenocarcinoma cells</td>
</tr>
<tr>
<td>SK-OV-3</td>
<td>human cisplatin-resistant SK-OV-3 cells</td>
</tr>
<tr>
<td>3/DDP cells</td>
<td>human cisplatin-resistant SK-OV-3 cells</td>
</tr>
<tr>
<td>Hep-G2 cells</td>
<td>human hepatocellular carcinoma cells</td>
</tr>
<tr>
<td>SK-OV-3 cells</td>
<td>human ovarian cancer cells</td>
</tr>
<tr>
<td>HeLa cells</td>
<td>human sarcoma HeLa cancer cells</td>
</tr>
<tr>
<td>HL-7702 cells</td>
<td>human normal hepatocytes cells</td>
</tr>
<tr>
<td>PI</td>
<td>propidium iodide</td>
</tr>
<tr>
<td>Δψ</td>
<td>mitochondrial membrane potential</td>
</tr>
<tr>
<td>JC-1</td>
<td>5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine</td>
</tr>
</tbody>
</table>
Experimental methods

**Materials.** Tris, RNase A, and propidium iodide (PI) were purchased from Sigma. The antibody of c-myc, hTERT, 53BP1, Cdc25 C, cyclin B, CDK2, apaf-1 and cytochrome c were purchased from Abcam. Unless otherwise stated, spectroscopic titration experiments were carried out in 10 mM Tris-HCl (pH 7.35) containing 100 mM KCl. The total RNA isolation kit and the two-step RT-PCR kit were purchased from TIANGEN. All tumor cell lines (HeLa, Hep-G2, SK-OV-3, MGC80-3, SK-OV-3/DDP tumor cells and one normal HL-7702 cells) were obtained from the Shanghai Institute for Biological Science (China). Stock solutions of the H-MeOBC ligand and its two Pt(II) complexes (2.0×10⁻³ M) were made in DMSO, and further dilutions to working concentrations were made with corresponding buffer.

**Instrumentation.** Infrared spectra were obtained on a Perkine Elmer FT-IR Spectrometer. Elemental analyses (C, H, N) were carried out on a Perkin Elmer Series II CHNS/O 2400 elemental analyser. NMR spectra were recorded on a Bruker AV-500 NMR spectrometer. Fluorescence measurements were performed on a Shimadzu RF-5301/PC spectro fluorophotometer. ESI-MS spectra were obtained on Thermofisher Scientific Exactive LC-MS spectrometer (ThermalElectronic, USA). The circular dichroic spectra of DNA were obtained on a JASCO J-810 automatic recording spectropolarimeter operating at 25 °C. The region between 200 and 400 nm was scanned for each sample. MTT assay was performed on M1000 microplate reader (Tecan Trading Co. Ltd, Shanghai, China). Cell cycle and apoptosis analysis was recorded on FACS Aria II Flow Cytometer (BD Biocisences, San Jose, USA).

**Cytotoxicity assay.** The cell culture was maintained on RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin in 25 cm² culture flasks at 37 °C humidified atmosphere with 5% CO₂.
All the cells to be tested in the following assays have a passage number of 3-6.

Cells $5.0 \times 10^3$ (HeLa, Hep-G2, SK-OV-3, MGC80-3, SK-OV-3/DDP tumor cells and one normal HL-7702 cells) per well were seeded in triplicate in 96-well plates and incubated for 24 h at 37 °C and 5% CO$_2$/95% air. Then graded amounts of compound were added to the wells in 10 µL of FBS free culture medium and the plates were incubated in a 5% CO$_2$ humidified atmosphere for 48 h. Six replica wells were used as controls. Cells were grew for 12 h before treatment to reach 70% confluency and 20 µL of tested various concentrations of compounds were added to each well. The final concentration of the tested compounds were kept at 1.25, 2.5, 5, 10, 20, 40, 50, 60, 100, 150 µM, respectively. After 48 h of culture, 0.1 mg of MTT (in 20 µL of PBS) was added to each well, and cells were incubated at 37 °C for 6 h. The formed formazan crystals were then dissolved in 100 µL of DMSO and the absorbance was read by enzyme labeling instrument with 490/630 nm double wavelength measurement. The final IC$_{50}$ values were calculated by the Bliss method ($n = 5$). All tests were repeated in at least three independent trials.

**Cellular uptake of Pt1 and Pt2 in SK-OV-3/DDP cells.** The SK-OV-3/DDP tumor cells (~10 million cells) were treated with Pt1 (10.0 µM), Pt2 (0.5 µM) and cisplatin (70.0 µM) for 24 h at 37 °C in a humidified 5% CO$_2$ incubator. The spent media was removed, and the cells were washed with 5 mL of PBS, scraped, and collected in 5 mL of PBS. The scrapped cells were spun down, by centrifuging at 2500 rpm for 10 min. The cell pellet obtained was dissolved in 1 M NaOH (1 mL) and diluted with 2% (v/v) HNO$_3$ (5 mL) for determining whole cell cobalt content. Another set was treated similarly, nuclear fraction, nuclear proteins, membrane proteins and cytoplasmic protein were isolated as described by Schreiber et al $^1$, and the final solution was made up to 5 mL using 2% (v/v) HNO$_3$. The amount of cobalt
taken up by the cells was determined by ICP-MS. The instrument was calibrated for Pt complexes using standard solutions containing 10, 50, 100, 500 and 1000 ppb Pt.

**Cell apoptosis analysis.** Apoptosis was detected by flow cytometric analysis of annexin V staining. Annexin V-FITC vs PI assay was performed as previously described \(^1\)-\(^3\). Briefly, adherent SK-OV-3/DDP cancer cells were harvested and suspended in the annexin-binding buffer (5×10\(^5\) cells/mL). Then, the SK-OV-3/DDP cancer cells after treated with Pt\(_1\) (10.0 \(\mu\)M), cisplatin (70.0 \(\mu\)M) and Pt\(_2\) (0.5 \(\mu\)M) were incubated with annexin V-FITC and PI for 1 h at room temperature in the dark and immediately analyzed by flow cytometry. The data are presented as biparametric dot plots showing PI red fluorescence vs annexin V-FITC green fluorescence.

**Cell cycle analysis.** In cell cycle analysis, the SK-OV-3/DDP cancer cells were maintained with 10% fetal calf serum in 5\% CO\(_2\) at 37 \(^\circ\)C. The cells after after treated with Pt\(_1\) (10.0 \(\mu\)M) and Pt\(_2\) (0.5 \(\mu\)M) were harvested by trypsinization and rinsed with PBS. After centrifugation, the pellet (10\(^5\)–10\(^6\) cells) was suspended in 1 mL PBS. The cells were washed in PBS and fixed with ice-cold 70\% ethanol in PBS under violent shaking. Cells 1 × 10\(^6\) were centrifuged and resuspended in a staining solution (0.5 mL of PBS containing 50 \(\mu\)g/mL PI and 75 kU/mL RNase A) for 30 min at room temperature in the dark. Finally, the cell cycle was analyzed by FACS Calibur flow cytometer (BD) and the cell cycle distribution and percentage of apoptotic cells were analyzed using Cell Quest (BDIS) and ModFit LT (Verity Software House, Topsham, ME).

**Induction of ROS in SK-OV-3/DDP cells.** DCFH-DA is a freely permeable tracer specific for ROS. At the same time, DCFH-DA can be deacetylated by intracellular esterase to the non-fluorescent DCFH which is oxidized by ROS to the fluorescent compound 2',7'-dichloroflorescein (DCF). Therefore, the fluorescence intensity of
DCF is proportional to the amount of ROS produced by the cells $^{4-6}$. T-24 cells $1 \times 10^6$ were exposed to $\text{Pt1} (10.0 \ \mu\text{M})$ and $\text{Pt2} (0.5 \ \mu\text{M})$ for 24 h, respectively, and 1 mM H$_2$O$_2$ used as a positive control of ROS production. After the exposure, cells were harvested, washed once with ice-cold PBS and incubated with DCFH-DA (100 $\mu$M in a final concentration) at 37 ºC for 15 min in the dark $^{5,6}$. Finally, the cells were washed again and maintained in 1 mL PBS. The ROS generation was assessed from 10,000 cells each sample by flow cytometric analysis with excitation and emission wavelengths of 488 and 530 nm, respectively.

$\Delta \psi_m$ loss. The loss of mitochondrial membrane potential ($\Delta \psi$) was assessed using a lipophilic cationic fluorescent probe, JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine; Beyotime). SK-OV-3/DDP tumor cells treated with $\text{Pt1} (10.0 \ \mu\text{M})$ and $\text{Pt2} (0.5 \ \mu\text{M})$ for 24 h were incubated with 5 $\mu$g/mL JC-1 for 30 min at 37 ºC and examined under the fluorescence microscopy. The emission fluorescence for JC-1 was monitored at 530 and 590 nm, under the excitation wavelength at 488 nm. These cells were treated with $\text{Pt1} (10.0 \ \mu\text{M})$ and $\text{Pt2} (0.5 \ \mu\text{M})$ for 24 h and then analyzed by JC-1 flow cytometry.

Induction of $\text{Ca}^{2+}$ fluctuation in SK-OV-3/DDP cells. The level of intracellular free $\text{Ca}^{2+}$ is decided by using a fluorescent dye Fluo-3 AM which can across the cell membrane and be cut into Fluo-3 by intracellular esterase. The Fluo-3 can specifically combine with the $\text{Ca}^{2+}$ and has a strong fluorescence with an excitation wavelength of 488 nm. After exposed to $\text{Pt1} (10.0 \ \mu\text{M})$ and $\text{Pt2} (0.5 \ \mu\text{M})$ for 24 h, respectively, the SK-OV-3/DDP tumor cells were harvested and washed twice with PBS, then resuspended in Fluo-3 AM (5.0 mM) for 30 min in dark. Detection of intracellular $\text{Ca}^{2+}$ was carried by Flow cytometer at 525 nm excitation wavelength.

Telomerase activity. The telomerase extract was prepared from the SK-OV-3/DDP
cance cells: a total of $5 \times 10^6$ SK-OV-3/DDP tumour cells untreated or treated with $\text{Pt}_1$ (10.0 $\mu$M) and $\text{Pt}_2$ (0.5 $\mu$M) were pelleted, and the cells were washed with 5 mL of PBS, scraped and lysed for 30 min on ice. Finally, the lysate was centrifuged at 13000 rpm for 30 min at 4 °C; the supernatant was collected and stored at −80 °C before use. The TRAP assay was performed by following previously published procedures. Telomerase extract was prepared from SK-OV-3/DDP cancer cells. A modified version of the TRAP assay was used. PCR was performed in a final 50 mL reaction volume composed of reaction mix (45.0 mL) containing Tris-HCl (20 mM, pH 8.0), deoxynucleotide triphosphates (50 mM), MgCl$_2$ (1.5 mM), KCl (63 mM), EGTA (1 mM), Tween-20 (0.005%), BSA (20 mg/mL), primer H21T (3.5 pmol; 5'-G$_3$T$_2$AG$_3$3'), primer TS (18 pmol; 5'-AATCCGTCGAGCAGAGTT-3'), primer Cxext (22.5 pmol; 5'-GTGCCCTTACCCTTACCCTCACCTA-3'), primer NT (7.5 pmol; 5'-ATCGCTTCTCAGGCTTTT-3'), TSNT internal control (0.01 amol; 5'-ATTCCGTCGAGCAGTTAAAAGGCGAGAAGCGAT-3'), Taq DNA polymerase (2.5 U), and telomerase (100 ng). Compounds or distilled water was added (5 mL). PCR was performed in an Eppendorf Master cycler equipped with a hot lid and incubated for 30 min at 30 °C, followed by 92 °C 30 s, 52 °C 30 s, and 72 °C 30 s for 30 cycles. After amplification, loading buffer (8 mL; 5×TBE buffer, 0.2% bromophenol blue, and 0.2% xylene cyanol) was added to the reaction. An aliquot (15 mL) was loaded onto a nondenaturing acrylamide gel (16%; 19:1) in 1×TBE buffer and resolved at 200 V for 1.5 h. Gels were fixed and then stained with AgNO$_3$.

**RNA extraction.** SK-OV-3/DDP tumour cells pellets harvested from each well of the culture plates were lysed in RZ Lysis solution. RNA was extracted with RNAsimple Total RNA kit (TIANGEN) according to manufacturer’s protocol and eluted in distilled, deionized water with 0.1% diethyl pyrocarbonate (DEPC) to a final
volume of 50 μL. RNA was stored at −150 °C before use.

**RT-PCR assay.** Total RNA was used as a template for reverse transcription using the following protocol: each 20 μL reaction contained 2.0 μL 10× RT mix., 2.0 μL dNTP (2.5 mM), 2.0 μL Oligo-dT15 primer, 1.0 μL Quant Reverse Transcriptase, 10 μL DEPC-H₂O, and 2 μg of total RNA. Briefly, RNA and oligo dT15 primer was incubated at 37 °C for 60 min and then immediately placed on ice. Finally, the reacted solution was stored at −80 °C. Real-time PCR was performed on 7500fast Real-Time PCR (ABI Co. Ltd, USA) by using 2.5×RealMasterMix/20×SYBR solution (TIANGEN), according to the manufacturer’s protocol. The total volume of 20.0 μL real-time RT-PCR reaction mixtures contained 9.0 μL of 2.5×RealMasterMix/20×SYBR solution, 0.25 μM each of forward and reverse primers, 1.0 μL of cDNA, and nuclease-free water. The program used for all genes consisted of a denaturing cycle of 3 min at 95 °C, 45 cycles of PCR (95 °C for 20 s, 58 °C for 30 s, and 68 °C for 30 s), a melting cycle consisting of 95 °C for 15 s, 65 °C for 15 s, and a step cycle starting at 65 °C with a 0.2 °C/s transition rate to 95 °C. The specificity of the real-time RT-PCR product was confirmed by melting curve analysis. The PCR product sizes were confirmed by agarose gel electrophoresis and ethidium bromide staining. Three replications were performed, and then hTERT and c-myc mRNA levels were normalized with the GAPDH mRNA level of each sample. Results of real-time PCR were analyzed using the 2^−ΔΔCT method in the program Origin 8.0 to compare the transcriptional levels of hTERT and c-myc genes in each sample relative to nondrug treated control.

**Western blotting.** The SK-OV-3/DDP tumor cells after treated with Pt1 (10.0 μM), Pt2 (0.5 μM) and cisplatin (70.0 μM) harvested from each well of the culture plates were lysed in 150 μL of extraction buffer consisting of 149 μL of RIPA Lysis
Buffer and 1 μL PMSF (100 mM). The suspension was centrifuged at 10000 rpm at 4 °C for 10 min, and the supernatant (10 μL for each sample) was loaded onto 10% polyacrylamide gel and then transferred to a microporous polyvinylidene difluoride (PVDF) membrane. Western blotting was performed using anti- c-myc, hTERT, 53BP1, Cdc25 C, cyclin B, CDK2, apaf-1, cytochrome c and β-actin antibody and horseradish peroxidase-conjugated antiamouse or antirabbit secondary antibody. Protein bands were visualized using chemiluminescence substrate.

**Transfection assay.** After the SK-OV-3/DDP tumor cells (1.0 ×10⁶) were grew in 3 cm Petri dishes for 24 h, DNA transfections were performed using the following procedure. Firstly, 2.0 μg EGFP plasmid ¹⁰ and 2.0 μg c-myc plasmid ¹¹,¹² were cotranfected into T-24 cancer cells using Lipo2000 (Invitrogen). Then, Pt₁ (10.0 μM) and Pt₂ (0.5 μM) were added into medium, respectively, after 6.0 h of transfection. After another 24 h of drug treatment, the cells were imaged using Nikon TE2000 (Japan) scanning fluorescence microscope and studied by Luciferase Reporter Gene Assay Kit.

**Statistical analysis.** The experiments have been repeated from three to five times, and the results obtained were presented as means±standard deviation (SD). Significant changes were assessed by using Student’s *t* test for unpaired data, and p values of <0.05 were considered statistically significant.
References


